Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.

[1]  V. Beral,et al.  Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer , 2015, Nature Reviews Cancer.

[2]  Joshua M. Korn,et al.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.

[3]  A. Zee,et al.  Biobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methods , 2015, Scientific Reports.

[4]  L. Woelber,et al.  Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer , 2015, Front. Oncol..

[5]  Katja Kaipio,et al.  Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy. , 2015, Cancer research.

[6]  Jacobus Pfisterer,et al.  Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial , 2015, The Lancet. Oncology.

[7]  Carlos Caldas,et al.  Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts. , 2015, Cancer research.

[8]  J. Reis-Filho,et al.  Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure , 2015, Oncotarget.

[9]  G. Heinze,et al.  Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer. , 2015, Cancer letters.

[10]  A. Difeo,et al.  Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance , 2015, Oncotarget.

[11]  Gordon B Mills,et al.  Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours , 2015, Nature Communications.

[12]  Joshy George,et al.  Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.

[13]  J. Doroshow,et al.  Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Robert Langer,et al.  An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors , 2015, Science Translational Medicine.

[15]  James M. Olson,et al.  A technology platform to assess multiple cancer agents simultaneously within a patient’s tumor , 2015, Science Translational Medicine.

[16]  F. Lin,et al.  Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer , 2015, Oncotarget.

[17]  G. Inghirami,et al.  Stromal contribution to the colorectal cancer transcriptome , 2015, Nature Genetics.

[18]  Benjamin G. Bitler,et al.  Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers , 2015, Nature Medicine.

[19]  Evis Sala,et al.  Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis , 2015, PLoS medicine.

[20]  C. Wijmenga,et al.  Gene expression analysis identifies global gene dosage sensitivity in cancer , 2015, Nature Genetics.

[21]  Thomas O. McDonald,et al.  Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk TP53 Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence , 2014, Molecular Cancer Therapeutics.

[22]  N. Schultz,et al.  The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Sohrab P. Shah,et al.  Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution , 2014, Nature.

[24]  Marijn T. M. van Jaarsveld,et al.  Lysophospholipids secreted by splenic macrophages induce chemotherapy resistance via interference with the DNA damage response , 2014, Nature Communications.

[25]  Wei-Ting Hwang,et al.  Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis , 2014, Clinical Cancer Research.

[26]  D. Matei,et al.  The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer , 2014, Clinical Cancer Research.

[27]  R. Kimmig,et al.  ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance. , 2014, Clinical chemistry.

[28]  E. Goode,et al.  Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. , 2014, Journal of the National Cancer Institute.

[29]  Luca Magnani,et al.  Poised epigenetic states and acquired drug resistance in cancer , 2014, Nature Reviews Cancer.

[30]  Xiaoming Wang,et al.  Epithelial ovarian cancer: A case report , 2014, Experimental and therapeutic medicine.

[31]  James D. Brenton,et al.  Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes , 2014, PloS one.

[32]  Marcela Dávila López,et al.  Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions , 2014, Oncotarget.

[33]  L. Franke,et al.  ATR inhibition preferentially targets homologous recombination-deficient tumor cells , 2014, Oncogene.

[34]  Zachary C. Dobbin,et al.  Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer , 2014, Oncotarget.

[35]  Adam A. Margolin,et al.  Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer , 2014, Clinical Cancer Research.

[36]  E. Yang,et al.  An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer. , 2014, Gynecologic oncology.

[37]  J. Dou,et al.  Observation of ovarian cancer stem cell behavior and investigation of potential mechanisms of drug resistance in three-dimensional cell culture. , 2014, Journal of bioscience and bioengineering.

[38]  R. Zeillinger,et al.  BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD). , 2014, European journal of cancer.

[39]  Prahlad T. Ram,et al.  Hematogenous metastasis of ovarian cancer: rethinking mode of spread. , 2014, Cancer cell.

[40]  Sridhar Ramaswamy,et al.  Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility , 2014, Science.

[41]  D. Matei,et al.  Epithelial ovarian cancer experimental models , 2014, Oncogene.

[42]  N. Navin,et al.  Clonal Evolution in Breast Cancer Revealed by Single Nucleus Genome Sequencing , 2014, Nature.

[43]  D. Matei,et al.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[44]  Mahmood Ayub,et al.  Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer , 2014, Nature Medicine.

[45]  L. Galluzzi,et al.  Systems biology of cisplatin resistance: past, present and future , 2014, Cell Death and Disease.

[46]  S. Fox,et al.  Molecular correlates of platinum response in human high‐grade serous ovarian cancer patient‐derived xenografts , 2014, Molecular oncology.

[47]  L. Meng,et al.  The Role of BRCA Status on the Prognosis of Patients with Epithelial Ovarian Cancer: A Systematic Review of the Literature with a Meta-Analysis , 2014, PloS one.

[48]  R. Stephens,et al.  Pathway-Specific Engineered Mouse Allograft Models Functionally Recapitulate Human Serous Epithelial Ovarian Cancer , 2014, PloS one.

[49]  M. Gore,et al.  A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer , 2014, British Journal of Cancer.

[50]  Alfonso Valencia,et al.  Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment , 2014, Clinical Cancer Research.

[51]  N. Curtin,et al.  The Use of Ovarian Cancer Cells from Patients Undergoing Surgery to Generate Primary Cultures Capable of Undergoing Functional Analysis , 2014, PloS one.

[52]  E. Fuller,et al.  Culture Models to Define Key Mediators of Cancer Matrix Remodeling , 2014, Front. Oncol..

[53]  C. Annunziata,et al.  Recent Technological Advances in Using Mouse Models to Study Ovarian Cancer , 2014, Front. Oncol..

[54]  Clarence C Lee,et al.  Genomic and transcriptomic plasticity in treatment-naïve ovarian cancer , 2014, Genome research.

[55]  Manuel Hidalgo,et al.  Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.

[56]  Jinmin Zhao,et al.  In vitro ovarian cancer model based on three-dimensional agarose hydrogel , 2014, Journal of tissue engineering.

[57]  J. Sarkaria,et al.  Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer , 2014, Clinical Cancer Research.

[58]  Mallika Singh,et al.  Mouse tumour models to guide drug development and identify resistance mechanisms , 2014, The Journal of pathology.

[59]  U. Matulonis,et al.  Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer , 2013, Front. Oncol..

[60]  C. Scott,et al.  Patient-Derived Xenograft Models to Improve Targeted Therapy in Epithelial Ovarian Cancer Treatment , 2013, Front. Oncol..

[61]  J. Jonkers,et al.  Molecular Pathways Molecular Pathways : How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors ? , 2014 .

[62]  W. Barry,et al.  Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. , 2013, Gynecologic oncology.

[63]  H. Hollema,et al.  Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL , 2013, British Journal of Cancer.

[64]  Alan Ashworth,et al.  Mechanisms of resistance to therapies targeting BRCA-mutant cancers , 2013, Nature Medicine.

[65]  A. Rafii,et al.  Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation , 2013, Cell Death and Disease.

[66]  Li Ding,et al.  Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. , 2013, Cell reports.

[67]  S. Shah,et al.  Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research , 2013, PloS one.

[68]  Kwok-Kin Wong,et al.  New cast for a new era: preclinical cancer drug development revisited. , 2013, The Journal of clinical investigation.

[69]  G. Hannon,et al.  Patient-derived tumor xenografts: transforming clinical samples into mouse models. , 2013, Cancer research.

[70]  Ali Bashashati,et al.  Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling , 2013, The Journal of pathology.

[71]  R. Drapkin,et al.  Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms , 2013, Front. Oncol..

[72]  Peter Bouwman,et al.  A high-throughput functional complementation assay for classification of BRCA1 missense variants. , 2013, Cancer discovery.

[73]  C. Sander,et al.  Evaluating cell lines as tumour models by comparison of genomic profiles , 2013, Nature Communications.

[74]  D. Planchard,et al.  Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  K. Flatten,et al.  ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. , 2013, Cancer research.

[76]  D. Speicher,et al.  Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition , 2013, Cell cycle.

[77]  W. Bshara,et al.  Origin of the vasculature supporting growth of primary patient tumor xenografts , 2013, Journal of Translational Medicine.

[78]  N. Rosenfeld,et al.  Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.

[79]  Lin Feng,et al.  RIF1 Counteracts BRCA1-mediated End Resection during DNA Repair* , 2013, The Journal of Biological Chemistry.

[80]  Kate Lawrenson,et al.  A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro , 2013, Laboratory Investigation.

[81]  W. Sellers,et al.  Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance , 2013, Nature.

[82]  K. Cibulskis,et al.  Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. , 2012, The Journal of clinical investigation.

[83]  B. Vanderhyden,et al.  Technical challenges and limitations of current mouse models of ovarian cancer , 2012, Journal of Ovarian Research.

[84]  P. Maxwell,et al.  Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival. , 2012, Cancer research.

[85]  Robert Brown,et al.  Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling , 2012, Oncogene.

[86]  Anne-Marie Mes-Masson,et al.  Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer , 2012, BMC Cancer.

[87]  M. Yi,et al.  Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. , 2012, Cancer research.

[88]  M. Esteller,et al.  Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer , 2012, Clinical Cancer Research.

[89]  J. Delord,et al.  Implication of Tumor Microenvironment in Chemoresistance: Tumor-Associated Stromal Cells Protect Tumor Cells from Cell Death , 2012, International journal of molecular sciences.

[90]  Michael M Gottesman,et al.  Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes , 2012, Pharmacological Reviews.

[91]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[92]  D. Bowtell,et al.  The changing view of high-grade serous ovarian cancer. , 2012, Cancer research.

[93]  J. Malek,et al.  Mesenchymal Cell Interaction with Ovarian Cancer Cells Triggers Pro-Metastatic Properties , 2012, PloS one.

[94]  E. Voest,et al.  The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression , 2012, British Journal of Cancer.

[95]  D. Matei,et al.  Epigenetic resensitization to platinum in ovarian cancer. , 2012, Cancer research.

[96]  L. Galluzzi,et al.  Molecular mechanisms of cisplatin resistance , 2012, Oncogene.

[97]  Andrew L. Kung,et al.  A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response , 2012, Nature.

[98]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[99]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[100]  C. Creighton,et al.  High-grade serous ovarian cancer arises from fallopian tube in a mouse model , 2012, Proceedings of the National Academy of Sciences.

[101]  V. A. Flørenes,et al.  Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index , 2012, Cancer Chemotherapy and Pharmacology.

[102]  P. Borst,et al.  Drug resistance in the mouse cancer clinic. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[103]  Kylie L. Gorringe,et al.  An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. , 2012, The Journal of clinical investigation.

[104]  Jay W. Wright,et al.  BRCAness Profile of Sporadic Ovarian Cancer Predicts Disease Recurrence , 2012, PloS one.

[105]  Peter Bouwman,et al.  BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. , 2011, Cancer cell.

[106]  Davide Corà,et al.  A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.

[107]  J. Brenton,et al.  Evolution of platinum resistance in high-grade serous ovarian cancer. , 2011, The Lancet. Oncology.

[108]  G. Mills,et al.  Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth , 2011, Nature Medicine.

[109]  T. Ludwig,et al.  BRCA1 Tumor Suppression Depends on BRCT Phosphoprotein Binding, But Not Its E3 Ligase Activity , 2011, Science.

[110]  A. Jazaeri,et al.  Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. , 2011, Neoplasia.

[111]  Kenneth P. Nephew,et al.  Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.

[112]  R. J. Kelleher,et al.  Humanized Mouse Model of Ovarian Cancer Recapitulates Patient Solid Tumor Progression, Ascites Formation, and Metastasis , 2011, PloS one.

[113]  B. Monk,et al.  Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. , 2011, Gynecologic oncology.

[114]  H. Mackay,et al.  Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. , 2011, The Lancet. Oncology.

[115]  Georgia Sotiropoulou,et al.  DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. , 2011, Clinical chemistry.

[116]  Rochelle L. Garcia,et al.  Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  Lewis C Cantley,et al.  The APL paradigm and the "co-clinical trial" project. , 2011, Cancer discovery.

[118]  M. Hidalgo,et al.  A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer , 2011, Molecular Cancer Therapeutics.

[119]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[120]  R. Drapkin,et al.  Modeling high-grade serous ovarian carcinogenesis from the fallopian tube , 2011, Proceedings of the National Academy of Sciences.

[121]  Richard A. Moore,et al.  ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.

[122]  M. Gerlinger,et al.  How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine , 2010, British Journal of Cancer.

[123]  M. Pajic,et al.  Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo , 2010, Cell cycle.

[124]  D. Matei,et al.  A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum‐resistant, epithelial ovarian cancer , 2010, Cancer.

[125]  B. Karlan,et al.  Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[126]  R. Coleman,et al.  Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. , 2010, American journal of obstetrics and gynecology.

[127]  Thomas J. Hardcastle,et al.  Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma , 2010, Oncogene.

[128]  D. Adams,et al.  53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers , 2010, Nature Structural &Molecular Biology.

[129]  Y. Drew,et al.  Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors , 2010, Clinical Cancer Research.

[130]  Ie-Ming Shih,et al.  The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory , 2010, The American journal of surgical pathology.

[131]  B. Vanderhyden,et al.  Conditional Inactivation of Brca1, p53 and Rb in Mouse Ovaries Results in the Development of Leiomyosarcomas , 2009, PloS one.

[132]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[133]  Daniel Birnbaum,et al.  Gene expression profiling and prediction of clinical outcome in ovarian cancer. , 2009, Critical reviews in oncology/hematology.

[134]  Tsuyoshi Arai,et al.  Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents , 2009, Molecular Cancer Therapeutics.

[135]  J. Marto,et al.  Primary ex-vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis , 2009, Oncogene.

[136]  Brett L Carlson,et al.  Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. , 2009, Neuro-oncology.

[137]  Hans W. Nijman,et al.  Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer , 2008, Cancer Immunology, Immunotherapy.

[138]  Hui-Yi Lin,et al.  Effect of TRA-8 Anti-Death Receptor 5 Antibody in Combination With Chemotherapy in an Ex Vivo Human Ovarian Cancer Model , 2009, International Journal of Gynecologic Cancer.

[139]  Joshy George,et al.  Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas , 2009, Clinical Cancer Research.

[140]  H. Hollema,et al.  Survival-Related Profile, Pathways, and Transcription Factors in Ovarian Cancer , 2009, PLoS medicine.

[141]  F. Patel,et al.  Utility of Gene Promoter Methylation in Prediction of Response to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) , 2009, Cancer investigation.

[142]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[143]  A. Mes-Masson,et al.  Characterization of three new serous epithelial ovarian cancer cell lines , 2008, BMC Cancer.

[144]  M. Castiglione,et al.  Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[145]  B. Karlan,et al.  Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. , 2008, Cancer research.

[146]  J. Kigawa,et al.  Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma , 2008, Cancer science.

[147]  F. Couch,et al.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.

[148]  Jorge S. Reis-Filho,et al.  Resistance to therapy caused by intragenic deletion in BRCA2 , 2008, Nature.

[149]  Anil K Sood,et al.  Early events in the pathogenesis of epithelial ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[150]  J. Jonkers,et al.  Modeling therapy resistance in genetically engineered mouse cancer models. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[151]  Glenn Heller,et al.  Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer , 2007, Clinical Cancer Research.

[152]  A. V. D. Van Der Zee,et al.  Profiling studies in ovarian cancer: a review. , 2007, The oncologist.

[153]  Jos Jonkers,et al.  Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer , 2007, Proceedings of the National Academy of Sciences.

[154]  W. Grizzle,et al.  Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. , 2007, Gynecologic oncology.

[155]  Anil Potti,et al.  An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[156]  D. Xing,et al.  A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. , 2006, Cancer research.

[157]  S. Pignata,et al.  Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study. , 2005, Anticancer research.

[158]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[159]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[160]  Alison Stopeck,et al.  Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[161]  R. Coleman,et al.  Progression‐free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay , 2004, International Journal of Gynecologic Cancer.

[162]  Marie Joseph,et al.  Gene expression signature with independent prognostic significance in epithelial ovarian cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[163]  Robert Brown,et al.  The epigenetics of ovarian cancer drug resistance and resensitization. , 2004, American journal of obstetrics and gynecology.

[164]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[165]  Robert Brown,et al.  The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients , 2004, Clinical Cancer Research.

[166]  I. Shih,et al.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.

[167]  A. Maier,et al.  Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. , 2004, European journal of cancer.

[168]  T. Bauknecht,et al.  A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. , 2003, Journal of the National Cancer Institute.

[169]  Robert S Mannel,et al.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[170]  I. Shih,et al.  Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. , 2003, Journal of the National Cancer Institute.

[171]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[172]  H. Ozçelik,et al.  Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. , 2002, Cancer research.

[173]  E. Trimble,et al.  Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[174]  H. Varmus,et al.  Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. , 2002, Cancer cell.

[175]  R. L. Baldwin,et al.  BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. , 2000, Cancer research.

[176]  T. Fojo,et al.  Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer , 2000, Oncogene.

[177]  J. Herman,et al.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. , 2000, Journal of the National Cancer Institute.

[178]  P. Scheffer,et al.  Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system. , 2000, Gynecologic oncology.

[179]  Chun-Fang Xu,et al.  Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics , 1999, Oncogene.

[180]  M. Piver,et al.  Characterization of human ovarian carcinomas in a SCID mouse model. , 1999, Gynecologic oncology.

[181]  A. Godwin,et al.  High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[182]  H. Fiebig,et al.  The clonogenic assay with human tumor xenografts: evaluation, predictive value and application for drug screening. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[183]  M. Gore,et al.  Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. , 1990, Gynecologic oncology.

[184]  J. Smyth,et al.  Characterization and properties of nine human ovarian adenocarcinoma cell lines. , 1988, Cancer research.

[185]  W. Kleine.  Prognostic significance of growth characteristics of xenotransplanted ovarian carcinomas into nude mice. , 1986, Gynecologic oncology.

[186]  C. Krumdieck,et al.  A new instrument for the rapid preparation of tissue slices. , 1980, Analytical biochemistry.

[187]  J.,et al.  The New England Journal of Medicine. , 1961, Canadian Medical Association journal.

[188]  M. Piccart,et al.  An update on PARP inhibitors—moving to the adjuvant setting , 2015, Nature Reviews Clinical Oncology.

[189]  Klaus Pantel,et al.  Circulating tumor cells: liquid biopsy of cancer. , 2013, Clinical chemistry.

[190]  E. Obermayr,et al.  Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium. , 2013, Gynecologic oncology.

[191]  Shridar Ganesan,et al.  Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. , 2013, Cancer discovery.

[192]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[193]  R. Brentjens,et al.  Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer. , 2010, Discovery medicine.

[194]  Michael L Pearl,et al.  Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. , 2009, Gynecologic oncology.

[195]  D. Huntsman,et al.  Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. , 2005, Gynecologic oncology.

[196]  Ook.,et al.  CYCLOPHOSPHAMIDE AND CISPLATIN COMPARED WITH PACLITAXEL AND CISPLATIN IN PATIENTS WITH STAGE III AND STAGE IV OVARIAN CANCER , 2000 .

[197]  F. Parazzini,et al.  Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimen. , 1994, European journal of cancer.